Thorough QT study of ELND 005 in volunteers

Trial Profile

Thorough QT study of ELND 005 in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs ELND 005 (Primary) ; Moxifloxacin
  • Indications Alzheimer's disease; Bipolar disorders; Cognition disorders
  • Focus Adverse reactions
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 15 Jan 2015 New trial record
    • 24 Nov 2014 Results published in Transition Therapeutics media release.
    • 24 Nov 2014 Results data were presented at Clinical Trials in Alzheimer's Disease conference on November 2014, according to a Transition Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top